| 10.04 1.58 (18.68%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.93  |
1-year : | 13.94 |
| Resists | First : | 10.22 |
Second : | 11.93 |
| Pivot price | 7.49 |
|||
| Supports | First : | 6.86 |
Second : | 4.78 |
| MAs | MA(5) : | 8.25 |
MA(20) : | 7.26 |
| MA(100) : | 5.3 |
MA(250) : | 5.94 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 94.6 |
D(3) : | 88 |
| RSI | RSI(14): 81.1 |
|||
| 52-week | High : | 12.39 | Low : | 3.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GLUE ] has closed above the upper band by 22.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 136.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.24 - 10.28 | 10.28 - 10.32 |
| Low: | 8.44 - 8.48 | 8.48 - 8.51 |
| Close: | 9.97 - 10.04 | 10.04 - 10.12 |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Thu, 09 Oct 2025
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Sell (D)" Rating from Weiss Ratings - MarketBeat
Tue, 30 Sep 2025
Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects - Yahoo Finance
Tue, 23 Sep 2025
Monte Rosa Therapeutics presents new CDK2 degradation inducers - BioWorld MedTech
Tue, 16 Sep 2025
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? - Nasdaq
Tue, 16 Sep 2025
Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 100.3 (%) |
| Shares Short | 8,240 (K) |
| Shares Short P.Month | 8,320 (K) |
| EPS | 0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.34 |
| Profit Margin | 13.5 % |
| Operating Margin | -67.1 % |
| Return on Assets (ttm) | 2.6 % |
| Return on Equity (ttm) | 9.8 % |
| Qtrly Rev. Growth | 394 % |
| Gross Profit (p.s.) | 0.91 |
| Sales Per Share | 2.88 |
| EBITDA (p.s.) | 0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 28 (M) |
| Levered Free Cash Flow | 41 (M) |
| PE Ratio | 25.74 |
| PEG Ratio | 0 |
| Price to Book value | 2.31 |
| Price to Sales | 3.48 |
| Price to Cash Flow | 22.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|